➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Patent: 6,355,245

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,355,245
Title: C5-specific antibodies for the treatment of inflammatory diseases
Abstract:The use of anti-C5 antibodies, e.g., monoclonal antibodies, to treat glomerulonephritis (GN) is disclosed. The administration of such antibodies at low dosage levels has been found to significantly reduce glomerular inflammation/enlargement and other pathologic conditions associated with GN. Also disclosed are anti-C5 antibodies and anti-C5 antibody-encoding nucleic acid molecules. These antibodies are useful in the treatment of GN and other inflammatory conditions involving pathologic activation of the complement system.
Inventor(s): Evans; Mark J. (Cheshire, CT), Matis; Louis A. (Southport, CT), Mueller; Eileen Elliott (East Haven, CT), Nye; Steven H. (Mequon, WI), Rollins; Scott (Monroe, CT), Rother; Russell P. (Cheshire, CT), Springhorn; Jeremy P. (Cheshire, CT), Squinto; Stephen P. (Bethany, CT), Thomas; Thomas C. (Madison, CT), Wilkins; James A. (Woodbridge, CT)
Assignee: Alexion Pharmaceuticals, Inc. (Cheshire, CT)
Application Number:08/487,283
Patent Claims:see list of patent claims

Details for Patent 6,355,245

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Alexion Pharm SOLIRIS eculizumab INJECTABLE; IV (INFUSION) 125166 001 2007-03-16   Start Trial Alexion Pharmaceuticals, Inc. (Cheshire, CT) 2019-03-12 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.